Will the strength they find in each other be enough to overcome the hatred and abuse of others? The unlikely pair struggle through friendship and heartbreaks, betrayal and hardships, to find the deepest desire of their hearts. Lead Investors’ counsel in hundreds of venture financings, including investments in: Carta, Segment.A Better Place is the story of two boys from two completely different worlds struggling to find themselves amongst a whirlwind of confusion. Netli – US$170 million sale to Akamai Technologies Mellanox Technologies – US$6.9 billion sale to Nvidia, US$811 million purchase of EZ Chip, US$82 million purchase of Kotura, US$218 million purchase of Voltaire, and US$48 million purchase of IPtronics Integrated Device Technology – US$7.1 billion sale to Reneasas Integrated Device Technology – US$1.7 billion merger with Integrated Circuit Systems Greenplum – sale to EMC (confidential terms)

Mellanox Technologies – US$117 million IPO and follow-on public equity offering raising nearly US$100 million Integrated Device Technology – US$374 million convertible notes offering Technology IPOs and Follow-on Offerings – Company Representation Relypsa – US$1.53 billion sale to Galenica Group Pearl Therapeutics – US$1.15 billion sale to AstraZeneca Odonate Therapeutics – US$160 million initial public Modernizing Medicines – US$58 million acquisition of gMed KYTHERA Biopharmaceuticals – US$2.1 billion sale to Allergan Life Sciences IPOs and Follow-on Equity Offerings – Underwriters RepresentationĪlios BioPharma – US$1.75 billion sale to Johnson & JohnsonĪveXis – several follow-on equity public offerings raising nearly US$750 millionĬV Therapeutics – US$1.5 billion sale to Gilead Sciences following a successful defense against a hostile bid by Astellas PharmaĭVS Sciences – US$208 million sale to FluidigmĮnvoy Therapeutics – US$140 million sale to Takeda Pharmaceutical Revolution Medicines – US$230 million follow-on equity public offering

Relypsa – US$78 million IPO and multiple follow-on equity public offerings raising nearly US$300 million OncoMed Pharmaceuticals – US$87 million IPO and US$51 million follow-on equity public offering KYTHERA Biopharmaceuticals – US$80 million IPO and US$133 million follow-on offering Intermune –convertible notes offerings raising US$276 million, and several follow-on equity public offerings US$860 million Life Sciences IPOs and Follow-on Equity Offerings – Company RepresentationĪrdelyx – US$60 million IPO and several follow-on equity offerings raising nearly US$350 millionĪscendis Pharma – US$124 million IPO and several follow-on equity public offerings raising more than US$900 millionĬytomX Therapeutics – US$142 million follow-on equity public offering Roeder's representative transactions include:

A Better Place by Mark A. Roeder